NASDAQ
04.11.25 | 21:49
2,275 US-Dollar
-8,27 % -0,205
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.10. | C4 Therapeutics prices $125M equity offering with warrants | 6 | Seeking Alpha | ||
| 16.10. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering | 5 | GlobeNewswire (USA) | ||
| 16.10. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma | 122 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 01.10. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.09. | C4 Therapeutics stock price target raised to $10 by Wells Fargo on positive data | 10 | Investing.com | ||
| 23.09. | C4 Therapeutics: Wells Fargo verdoppelt Kursziel nach positiven Studiendaten | 5 | Investing.com Deutsch | ||
| 22.09. | Forecasting The Future: 4 Analyst Projections For C4 Therapeutics | 4 | Benzinga.com | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.09. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.09. | Myelom-Medikament von C4 Therapeutics zeigt 50-prozentige Ansprechrate in Studie | 1 | Investing.com Deutsch | ||
| 20.09. | C4 Therapeutics Reports Promising Phase 1 Results For Cemsidomide In R/R Multiple Myeloma | 1 | RTTNews | ||
| 20.09. | C4 Therapeutics' myeloma drug shows 50% response rate in trial | 2 | Investing.com | ||
| 20.09. | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 16.09. | Barclays bestätigt "Overweight"-Rating für C4 Therapeutics | 1 | Investing.com Deutsch | ||
| 16.09. | C4 Therapeutics stock rating reiterated as Overweight by Barclays | 3 | Investing.com | ||
| 16.09. | Why C4 Therapeutics Stock Crushed the Market on Monday | 3 | The Motley Fool | ||
| 15.09. | Stephens-Upgrade beflügelt C4 Therapeutics-Aktie mit über 125 % Kurspotenzial | 5 | Investing.com Deutsch | ||
| 15.09. | C4 Therapeutics stock surges after Stephens upgrade signals upside | 4 | Investing.com | ||
| 04.09. | C4 Therapeutics, Inc.: C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration | 301 | GlobeNewswire (Europe) | WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 04.09. | C4 Therapeutics stock initiated with Buy rating at Guggenheim on myeloma drug potential | 2 | Investing.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 2,160 | -0,92 % | INOVIO Pharmaceuticals, Inc.: INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults | Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need
INO-3107 previously received... ► Artikel lesen | |
| OCUGEN | 1,269 | -4,15 % | Ocugen Q3 2025 Earnings Preview | ||
| CELLDEX THERAPEUTICS | 21,400 | -0,93 % | Celldex Therapeutics, Inc.: Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition | --Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today positive data from the... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,956 | -2,20 % | Cardiff Oncology: Neue Impulse voraus? | Mit der Aktie von Cardiff Oncology haben Mitglieder von sharedealsPlus in der Vergangenheit mehrfach hervorragend verdient. Zuletzt konnten im Rahmen eines Daten-Run-up-Szenarios über 30% Kursgewinn... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,385 | 0,00 % | Coherus Oncology, Inc.: Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| NEOVACS | 0,032 | -9,22 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 | The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,870 | -4,32 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| ULTRAGENYX | 28,600 | -1,38 % | Ultragenyx Pharmaceutical Inc. - 8-K, Current Report | ||
| GYRE THERAPEUTICS | 6,800 | +6,25 % | Gyre Therapeutics Inc.: Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis | SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ... ► Artikel lesen | |
| BIOMEA FUSION | 1,250 | -4,21 % | Biomea Fusion, Inc.: Biomea Fusion to Present Poster Presentations at ObesityWeek2025 | ||
| GOSSAMER BIO | 2,010 | -2,90 % | Respira Therapeutics, Inc.: Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital | - Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and... ► Artikel lesen | |
| JANUX THERAPEUTICS | 27,080 | -1,17 % | Janux Therapeutics gains amid renewed takevover speculation | ||
| SAGIMET BIOSCIENCES | 7,000 | -0,71 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination | Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 1,385 | -2,12 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 10,780 | -4,01 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific | 4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration... ► Artikel lesen |
Das Unternehmen C4 THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,205 (-8,27 %) liegt der Kurs bei 2,275 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.